Table 1 Amoxicillin/ clavulanate (Amoxiclav) is highly potent against major causative agents of respiratory infections 
Note: +++ — high potency, ++ — moderate potency, 0 — no clinical potency, PRP — penicillin-resistant pneumococci, PSP — penicillin-susceptible pneumococci, MSSA — methicillin-susceptible Staphylococcus aureus.
Fig. 1. Patient Т. X-ray image at first visit: frontal and lateral view. Illustrations by A. A. Yanina
Antibacterial therapy of community-acquired pneumonia in adults 
Chronic obstructive pulmonary disease, diabetes mellitus, chronic cardiac failure, chronic renal disease, hepatic cirrhosis, alcoholism, drug addiction, exhaustion.
2 Administration: ≥ 2 days.
3 Not feasible for regions with resistivity of over 25% (Moscow, St. Petersburg).
Fig. 2. Patient Т. X-ray image at first visit (frontal and lateral view) after therapy. Illustrations by A. A. Yanina
Antibacterial therapy of infectious complications of chronic obstructive pulmonary disease (COPD)